ProShares Ultra NASDAQ Biotechnology
BIB
17 hedge funds and large institutions have $22.6M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 8 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
18% more capital invested
Capital invested by funds: $19.2M → $22.6M (+$3.37M)
23% less funds holding
Funds holding: 22 → 17 (-5)
51% less call options, than puts
Call options by funds: $8.68M | Put options by funds: $17.9M
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
+$1.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$789K |
| 3 |
Morgan Stanley
New York
|
+$598K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$302K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$182K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.92M |
| 2 |
Jane Street
New York
|
-$1.85M |
| 3 |
AP
Advisors Preferred
Rockville,
Maryland
|
-$1.39M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$636K |
| 5 |
Citigroup
New York
|
-$396K |
BIB Hedge Fund Activity: Q3 2014 in Review
17 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2014, worth a combined $22.6M — up 18% from $19.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BIB and 3 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Valentine Capital Asset Management, adding an estimated $1.2M. The largest seller was Susquehanna International Group, cutting an estimated $1.92M.
- 17 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2014, down from 22 in Q2 2014.
- Funds reported $22.6M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2014, up 18% quarter-over-quarter.
- 3 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2014 and 8 closed out, a net change of -5 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2014 was Valentine Capital Asset Management, an estimated $1.2M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2014 was Susquehanna International Group, an estimated $1.92M sold.
Based on aggregated 13F filings for Q3 2014.